Article Text
Statistics from Altmetric.com
In order to respond to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pandemic, all fields of medical and biological sciences are working to improve the understanding of coronavirus disease 2019 (COVID-19). In this race against time, studies are expeditiously conducted and journal review and acceptance processes accelerated. Although this approach dramatically reduced the time required to publish, could the quality of these new studies be affected? Indeed, reducing the review time may allow for errors or biases to be missed, jeopardising the validity of evidence-based medicine principles. Abundance of information can also be confusing for healthcare practitioners and governments.1 Moreover, redundancy in COVID-19 trials could lead to lost time and energy for research teams, scientific journals and reviewers.2
In order to explore this phenomenon, we used the Medline database …
Footnotes
Contributors All authors fulfill the ICMJE criteria of authorship. AB, KG, M-JD and TdV designed this work; AB and KG collected the data; AB, KG, M-JD and TdV analysed the data, wrote the draft of the manuscript, contributed to critical revisions of the manuscript and approved the final version of the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests Dr Alexandre Balaphas and Dr Gkoufa are running studies on COVID-19.
Patient consent for publication Patients or the public were not involved in the design, conduct, reporting or dissemination plans of our research.
Provenance and peer review Not commissioned; internally peer reviewed.